Chiasma's oral ocreotide controls acromegaly in some patients
This article was originally published in Scrip
Executive Summary
Chiasma is raising capital to fund a new drug application (NDA) submission to the US FDA for oral ocreotide in the treatment of acromegaly based on Phase III results that were published on 9 February in the Journal of Clinical Endocrinology and Metabolism (JCEM).
You may also be interested in...
Chiasma Responds To FDA Complete Response With 33% Staff Cut
With a near-term launch of Mycapssa unlikely, Chiasma cuts its commercial staff while it evaluates how to respond to an April complete response letter.
Lilly’s Mounjaro Diabetes Approval Is First Challenge To Novo’s GLP-1 Franchise
The GLP-1/GIP agonist tirzepatide is a key addition to Lilly’s commercial portfolio as the company leans on new products to deliver on volume-driven growth through the current decade.
AbbVie Ups Its IBD Game With Latest Crohn’s Data For Rinvoq
The leader in inflammatory bowel disease via Humira, AbbVie awaits a US FDA decision in June for Skyrizi in Crohn’s disease and plans to add a Crohn’s indication to Rinvoq’s ulcerative colitis approval.